Boston Scientific Corporation $BSX Shares Sold by Meiji Yasuda Asset Management Co Ltd.

Meiji Yasuda Asset Management Co Ltd. lessened its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 92,650 shares of the medical equipment provider’s stock after selling 3,905 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Boston Scientific were worth $9,347,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NS Partners Ltd grew its position in shares of Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares during the period. Bank Pictet & Cie Europe AG increased its position in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after acquiring an additional 21,173 shares during the period. Oppenheimer & Co. Inc. increased its position in shares of Boston Scientific by 18.8% during the 1st quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider’s stock valued at $3,987,000 after purchasing an additional 6,264 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in shares of Boston Scientific in the first quarter worth $8,234,000. Finally, Blue Trust Inc. boosted its position in Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider’s stock valued at $504,000 after purchasing an additional 575 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Barclays lifted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Citigroup reissued a “buy” rating and issued a $125.00 price target (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Royal Bank Of Canada reissued an “outperform” rating on shares of Boston Scientific in a research note on Thursday, July 24th. Finally, Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an “outperform” rating and a $118.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and an average target price of $117.50.

Boston Scientific Stock Performance

Shares of BSX stock opened at $107.14 on Monday. The company has a 50 day moving average price of $104.77 and a 200-day moving average price of $102.15. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $158.76 billion, a PE ratio of 63.78, a P/E/G ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $108.94.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The company’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.